Zura Bio And 2 Other Promising Penny Stocks For Your Watchlist

As U.S. stock indexes hit record highs amid optimism over trade discussions between the U.S. and China, investors are increasingly looking for opportunities beyond the major indices. Penny stocks, often associated with smaller or newer companies, remain a relevant investment area despite their somewhat outdated label. These stocks can offer significant growth potential when backed by strong financials, and we will explore several that stand out as promising candidates for those seeking hidden value in quality companies.

Top 10 Penny Stocks In The United States

Name Share Price Market Cap Financial Health Rating Dingdong (Cayman) (DDL) $1.91 $405.04M ★★★★★★ Waterdrop (WDH) $1.80 $643.76M ★★★★★☆ CuriosityStream (CURI) $4.41 $260.1M ★★★★★★ WM Technology (MAPS) $1.12 $203.51M ★★★★★★ GoodRx Holdings (GDRX) $3.77 $1.37B ★★★★★★ Sensus Healthcare (SRTS) $3.26 $54.91M ★★★★★★ Performance Shipping (PSHG) $2.01 $25.24M ★★★★★★ Golden Growers Cooperative (GGRO.U) $5.00 $77.45M ★★★★★★ BAB (BABB) $0.9925 $6.9M ★★★★★★ Lifetime Brands (LCUT) $3.75 $76.58M ★★★★★☆

Click here to see the full list of 353 stocks from our US Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Zura Bio

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Zura Bio Limited is a clinical-stage biotechnology company focused on developing medicines for immune and inflammatory disorders in the United States, with a market cap of $239.92 million.

Operations: Currently, there are no reported revenue segments for this clinical-stage biotechnology company.

Market Cap: $239.92M

Zura Bio, a clinical-stage biotechnology company, is currently pre-revenue with a market cap of US$239.92 million and no significant revenue streams. It possesses strong short-term financial health, with assets of US$157 million surpassing liabilities of US$18.7 million. Despite being debt-free and having a sufficient cash runway for over three years, the company faces challenges such as high share price volatility and an unprofitable status with increasing losses over five years. Recent executive changes include Kim Davis stepping in as interim CEO due to Robert Lisicki's medical leave, following Zura's removal from the S&P Global BMI Index in September 2025.

Click to explore a detailed breakdown of our findings in Zura Bio's financial health report. Gain insights into Zura Bio's outlook and expected performance with our report on the company's earnings estimates.ZURA Financial Position Analysis as at Oct 2025

Under Armour

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Under Armour, Inc., along with its subsidiaries, develops, markets, and distributes performance apparel, footwear, and accessories for men, women, and youth with a market cap of approximately $2.03 billion.

Story Continues

Operations: Under Armour generates revenue from various regions, with North America contributing $3.07 billion, EMEA bringing in $1.11 billion, Asia-Pacific accounting for $737 million, and Latin America adding $206 million.

Market Cap: $2.03B

Under Armour, Inc., with a market cap of US$2.03 billion, has recently turned profitable after five years of growth, although its operating cash flow remains negative. The company's financial position shows short-term assets exceeding both short and long-term liabilities. Despite experiencing a net loss in the first quarter of 2025, the loss was significantly reduced compared to the previous year. Recent shareholder activism focused on emissions targets did not result in approved proposals. Financial guidance for fiscal Q2 2026 anticipates revenue declines across key regions with potential operating income losses but slight adjusted earnings per share gains expected.

Unlock comprehensive insights into our analysis of Under Armour stock in this financial health report. Review our growth performance report to gain insights into Under Armour's future.UAA Debt to Equity History and Analysis as at Oct 2025

Elite Pharmaceuticals

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and selling oral controlled-release and generic pharmaceuticals with a market cap of $670.91 million.

Operations: The company's revenue is derived entirely from its Abbreviated New Drug Applications (ANDA) segment, which generated $105.45 million.

Market Cap: $670.91M

Elite Pharmaceuticals, Inc. has shown a significant revenue increase to US$40.21 million for the first quarter of 2025, up from US$18.8 million a year ago, although it remains unprofitable with a net loss of US$5.88 million. The company benefits from strong liquidity, with short-term assets surpassing both its short and long-term liabilities and having more cash than total debt. Despite its current losses, Elite's debt is well covered by operating cash flow and interest payments are comfortably managed by EBIT. However, insider selling has been significant recently and the stock trades substantially below estimated fair value.

Dive into the specifics of Elite Pharmaceuticals here with our thorough balance sheet health report. Understand Elite Pharmaceuticals' track record by examining our performance history report.ELTP Debt to Equity History and Analysis as at Oct 2025

Seize The Opportunity

Get an in-depth perspective on all 353 US Penny Stocks by using our screener here. Searching for a Fresh Perspective? AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ZURAUAA and ELTP.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments